Paweł Kawalec

Summary

Affiliation: Jagiellonian University
Country: Poland

Publications

  1. doi request reprint Effectiveness of targeted therapy in patients with previously untreated metastatic breast cancer: a systematic review and meta-analysis
    Paweł Kawalec
    Jagiellonian University Medical College, Faculty of Health Sciences, Institute of Public Health, Department of Drug Management, Krakow, Poland Electronic address
    Clin Breast Cancer 15:90-100.e1. 2015
  2. doi request reprint Pregabalin for the treatment of social anxiety disorder
    Paweł Kawalec
    Jagiellonian University Medical College, Department of Drug Management, Faculty of Health Sciences, Grzegorzecka 20, PL 31 531 Kraków, Poland
    Expert Opin Investig Drugs 24:585-94. 2015
  3. pmc Sipuleucel-T immunotherapy for castration-resistant prostate cancer. A systematic review and meta-analysis
    Paweł Kawalec
    Drug Management Department, Institute of Public Health, Faculty of Health Sciences, Jagiellonian University, Krakow, Poland
    Arch Med Sci 8:767-75. 2012
  4. pmc The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis
    Paweł Kawalec
    Drug Management Department, Institute of Public Health, Faculty of Health Sciences, Jagiellonian University, 20 Grzegorzecka St, 31 531, Krakow, Poland
    Clin Rheumatol 32:1415-24. 2013
  5. ncbi request reprint [The evaluation of cost-effectiveness and cost-utility of valganciclovir for the prophylaxis of cytomegalovirus disease to 200 days after kidney transplantation]
    Paweł Kawalec
    Uniwersytet Jagielloński w Krakowie, Zakład Gospodarki Lekiem, Instytut Zdrowia Publicznego, Wydział Nauk o Zdrowiu
    Pol Merkur Lekarski 34:332-8. 2013
  6. ncbi request reprint [Clinical efficacy and safety of prolonged use of the valganciclovir for the treatment of cytomegalovirus disease in patients after kidney transplantation]
    Paweł Kawalec
    Uniwersytet Jagielloński w Krakowie, Wydział Nauk o Zdrowiu, Instytut Zdrowia Publicznego, Zaklad Gospodarki Lekiem
    Pol Merkur Lekarski 35:10-3. 2013
  7. pmc Efavirenz-Based Regimens in Antiretroviral-Naive HIV-Infected Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Joanna Kryst
    Independent EBM expert, Krakow, Poland
    PLoS ONE 10:e0124279. 2015
  8. pmc Nevirapine-based regimens in HIV-infected antiretroviral-naive patients: systematic review and meta-analysis of randomized controlled trials
    Paweł Kawalec
    Drug Management Department, Institute of Public Health, Faculty of Health Sciences, Jagiellonian University, Krakow, Poland Centrum HTA Sp z o o Sp komandytowa, Krakow, Poland
    PLoS ONE 8:e76587. 2013
  9. doi request reprint Economic evaluation of single-pill combination of indapamide and amlodipine in the treatment of arterial hypertension in the Polish setting
    Paweł Kawalec
    Departament of Drug Management, Institute of Public Health, Faculty of Health Sciences, Jagiellonian University Collegium Medicum, Krakow, Poland
    Kardiol Pol 73:768-80. 2015
  10. doi request reprint The indirect costs of multiple sclerosis: systematic review and meta-analysis
    Ewa Stawowczyk
    a 1 HTA Expert, Krakow, 31 531, Poland
    Expert Rev Pharmacoecon Outcomes Res 15:759-86. 2015

Collaborators

  • Gabriel Nowak
  • Maria Boratynska
  • Joanna Kryst
  • Ewa Stawowczyk
  • Przemysław Holko
  • Nevena Sović
  • Krzysztof Piotr Malinowski
  • Andrzej Pilc
  • Paweł Moćko
  • Piotr Jankowski
  • Kalina Kawecka-Jaszcz
  • Alejandra Duenas
  • Andrzej Pajak
  • Urszula Stepaniak
  • Renata Wolfshaut-Wolak

Detail Information

Publications16

  1. doi request reprint Effectiveness of targeted therapy in patients with previously untreated metastatic breast cancer: a systematic review and meta-analysis
    Paweł Kawalec
    Jagiellonian University Medical College, Faculty of Health Sciences, Institute of Public Health, Department of Drug Management, Krakow, Poland Electronic address
    Clin Breast Cancer 15:90-100.e1. 2015
    ..The addition of targeted therapy to chemotherapy or endocrine therapy using HER2 and HR status significantly improved ORR, PFS, and OS in patients with previously untreated MBC...
  2. doi request reprint Pregabalin for the treatment of social anxiety disorder
    Paweł Kawalec
    Jagiellonian University Medical College, Department of Drug Management, Faculty of Health Sciences, Grzegorzecka 20, PL 31 531 Kraków, Poland
    Expert Opin Investig Drugs 24:585-94. 2015
    ..However, new effective therapeutic options are still needed. Pregabalin is a novel anxiolytic, which seems to be a promising therapy for SAD...
  3. pmc Sipuleucel-T immunotherapy for castration-resistant prostate cancer. A systematic review and meta-analysis
    Paweł Kawalec
    Drug Management Department, Institute of Public Health, Faculty of Health Sciences, Jagiellonian University, Krakow, Poland
    Arch Med Sci 8:767-75. 2012
    ..It is assumed to be associated with less adverse events than conventional docetaxel-based chemotherapy...
  4. pmc The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis
    Paweł Kawalec
    Drug Management Department, Institute of Public Health, Faculty of Health Sciences, Jagiellonian University, 20 Grzegorzecka St, 31 531, Krakow, Poland
    Clin Rheumatol 32:1415-24. 2013
    ..In addition, tofacitinib might provide an effective treatment option compared to intravenous or subcutaneous biological DMARDs, as suggested by the result of the comparison made regarding tofacitinib vs. adalimumab ACR50 response rate...
  5. ncbi request reprint [The evaluation of cost-effectiveness and cost-utility of valganciclovir for the prophylaxis of cytomegalovirus disease to 200 days after kidney transplantation]
    Paweł Kawalec
    Uniwersytet Jagielloński w Krakowie, Zakład Gospodarki Lekiem, Instytut Zdrowia Publicznego, Wydział Nauk o Zdrowiu
    Pol Merkur Lekarski 34:332-8. 2013
    ..z o.o.) from 110 to 200 days, in the high risk patients group after kidney transplant (seronegative recipient and infected donor, D+/R-). The analysis was performed from the Polish healthcare payer's perspective...
  6. ncbi request reprint [Clinical efficacy and safety of prolonged use of the valganciclovir for the treatment of cytomegalovirus disease in patients after kidney transplantation]
    Paweł Kawalec
    Uniwersytet Jagielloński w Krakowie, Wydział Nauk o Zdrowiu, Instytut Zdrowia Publicznego, Zaklad Gospodarki Lekiem
    Pol Merkur Lekarski 35:10-3. 2013
    ....
  7. pmc Efavirenz-Based Regimens in Antiretroviral-Naive HIV-Infected Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Joanna Kryst
    Independent EBM expert, Krakow, Poland
    PLoS ONE 10:e0124279. 2015
    ..Beneficial safety profile of InSTI-based and CCR5-based therapy over efavirenz-based treatment needs further studies. ..
  8. pmc Nevirapine-based regimens in HIV-infected antiretroviral-naive patients: systematic review and meta-analysis of randomized controlled trials
    Paweł Kawalec
    Drug Management Department, Institute of Public Health, Faculty of Health Sciences, Jagiellonian University, Krakow, Poland Centrum HTA Sp z o o Sp komandytowa, Krakow, Poland
    PLoS ONE 8:e76587. 2013
    ..Nevirapine belongs to the group of non-nucleoside reverse transcriptase inhibitors (NNRTIs) and is commonly administered in first-line treatment of HIV infection...
  9. doi request reprint Economic evaluation of single-pill combination of indapamide and amlodipine in the treatment of arterial hypertension in the Polish setting
    Paweł Kawalec
    Departament of Drug Management, Institute of Public Health, Faculty of Health Sciences, Jagiellonian University Collegium Medicum, Krakow, Poland
    Kardiol Pol 73:768-80. 2015
    ..The current ESC/ESH 2013 guidelines for the first time recommend treatment with a combination of thiazide-like diuretic with calcium channel blocker. Currently, no such combination is reimbursed from public funds in Poland...
  10. doi request reprint The indirect costs of multiple sclerosis: systematic review and meta-analysis
    Ewa Stawowczyk
    a 1 HTA Expert, Krakow, 31 531, Poland
    Expert Rev Pharmacoecon Outcomes Res 15:759-86. 2015
    ..Costs were higher for Europe than for other continents and were also higher for patients with a higher Expanded Disability Status Scale score. ..
  11. ncbi request reprint [Administration of conestat alfa, human C1 esterase inhibitor and icatibant in the treatment of acute angioedema attacks in adults with hereditary angioedema due to C1 esterase inhibitor deficiency. Treatment comparison based on systematic review results]
    Paweł Kawalec
    Zakład Gospodarki Lekiem, Instytut Zdrowia Publicznego, Wydział Nauk o Zdrowiu UJ, ul Grzegorzecka 20, Krakow
    Pneumonol Alergol Pol 81:95-104. 2013
    ..The aim of this study is a comparison of the clinical effectiveness of conestat alfa, human C1 esterase inhibitor (C1INH), and icatibant in the treatment of acute angioedema attacks in adults with HAE...
  12. doi request reprint Cost-effectiveness of a cardiovascular disease primary prevention programme in a primary health care setting. Results of the Polish part of the EUROACTION project
    Nevena Sović
    Institute of Public Health, Faculty of Health Sciences, Jagiellonian University Collegium Medicum, Krakow, Poland
    Kardiol Pol 71:702-11. 2013
    ..However, introducing them broadly into clinical practice would have a significant impact on the healthcare budget, and requires careful consideration...
  13. doi request reprint Economic evaluation of sipuleucel-T immunotherapy in castration-resistant prostate cancer
    Przemysław Holko
    Centrum HTA, Krakow, Poland
    Expert Rev Anticancer Ther 14:63-73. 2014
    ..Accounting for crossover treatment in control patients improves sipuleucel-T's value (US$132,000 per QALY saved) although further investigation is necessary. ..